Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.
Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepatitis C is caused by hepatitis C virus and affects between 130–150 million people globally every year of which approximately 700 000 people die from hepatitis C-related liver diseases. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.

The global Hepatitis C Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Hepatitis C Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hepatitis C Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Hepatitis C Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Hepatitis C Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Gilead sciences
Abbvi
Johnson & Johnson
Merck
Glaxosmithkline
Novartis
Bristol-Myers Squibb
Roche

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
By Drug Class
Anti-Viral
Immuno-modulators
Others
By Medicine System
Allopathic
Alternative
Others

Segment by Application
Hospitals
Clinics